Duopharma Biotech Berhad Profit Margin

The latest profit margin for 7148.KL is 11.0% as of June 2026. That compares with 8.63% in the prior-year period — up 27.5% year over year. That is below the sector sector average of 13.4%. Investors often review this figure alongside Duopharma Biotech Berhad's historical trend and sector peers before judging valuation or financial health.

Over the past year, 7148.KL's profit margin moved from 8.63% to 11.0% — a 27.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Duopharma Biotech Berhad's valuation or profitability profile.

Against its sector companies, 7148.KL currently prints 11.0% for profit margin, while the sector average sits near 13.4%. That is roughly 18.0% below the sector mean. Large gaps often invite a closer look at Duopharma Biotech Berhad's growth, margins, and balance sheet.

Profit Margin shows how effectively Duopharma Biotech Berhad converts resources into returns. At 11.0%, 7148.KL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 8.63% in the prior-year period — up 27.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 7148.KL's profit margin (11.0%), review year-over-year change from 8.63%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.